Published in Bull Cancer on January 01, 1987
The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol (1994) 1.48
Medical termination of pregnancy. BMJ (1990) 1.17
Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res (2007) 1.15
Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med (2014) 0.92
Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther (2013) 0.91
Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer. Mol Endocrinol (2010) 0.84
Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry (1992) 0.82
Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Breast Cancer Res Treat (2011) 0.81
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. Springerplus (2016) 0.80
Antiprogestins in gynecological diseases. Reproduction (2014) 0.78
The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature. Cancer Prev Res (Phila) (2012) 0.77
Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol (2015) 0.75
Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. A large-scale French experience. N Engl J Med (1990) 2.66
A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell (1980) 2.28
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res (2001) 2.21
Postcoital contraception: myth or reality? Lancet (1991) 2.16
Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res (1982) 2.15
Inhibition of breast cancer growth by suramin. J Natl Cancer Inst (1992) 2.10
Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med (1993) 2.00
Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res (1993) 1.98
RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med (1997) 1.80
Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol (2004) 1.79
Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet (1989) 1.77
Estradiol induced proteins in the MCF7 human breast cancer cell line. Biochem Biophys Res Commun (1979) 1.76
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer (2001) 1.66
Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int (1978) 1.56
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer (2004) 1.52
Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol (1994) 1.52
Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril (1991) 1.51
Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology (1986) 1.50
Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res (1989) 1.48
Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci U S A (1992) 1.48
Treatment of endometriosis with the antiprogesterone mifepristone (RU486) Fertil Steril (1996) 1.48
Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene (1990) 1.47
Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med (2011) 1.45
Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res (1998) 1.37
Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene (1995) 1.35
Immunogold localization of beta-1,3-glucanases in two plants infected by vascular wilt fungi. Plant Cell (1989) 1.35
Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res (1989) 1.34
Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res (1987) 1.33
Aberrant recombination events in B cell lines derived from a kappa-deficient human. Nucleic Acids Res (1985) 1.33
Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis (1997) 1.32
Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. J Biol Chem (1984) 1.31
In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res (1988) 1.30
Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res (2000) 1.30
Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun (1987) 1.29
Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol (1983) 1.28
Mobile health to improve tuberculosis care and control: a call worth making. Int J Tuberc Lung Dis (2013) 1.27
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. Blood (1984) 1.26
HDL-cholesterol and breast cancer: a joint study in northern Italy and southern France. Int J Epidemiol (1993) 1.22
Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone). N Engl J Med (1986) 1.21
Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers (2000) 1.20
Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J Clin Endocrinol Metab (1982) 1.20
Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem (1981) 1.20
Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology (1980) 1.20
MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res (1991) 1.19
A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells. Oncogene (2001) 1.19
Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. Int J Cancer (1998) 1.18
FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol Endocrinol (1998) 1.17
Expression of human sequences related to those of mouse mammary tumor virus. J Virol (1988) 1.16
Conservative surgery for low rectal carcinoma after high-dose radiation. Functional and oncologic results. Ann Surg (1995) 1.15
Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF7 breast cancer cells and mapping on chromosome 11. Mol Endocrinol (1988) 1.15
Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells. Nucleic Acids Res (1988) 1.15
Widespread use of serological tests for tuberculosis: data from 22 high-burden countries. Eur Respir J (2012) 1.15
Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol Endocrinol (1994) 1.14
Phosphorylation, glycosylation, and proteolytic activity of the 52-kD estrogen-induced protein secreted by MCF7 cells. J Cell Biol (1987) 1.13
p53 mutations in ovarian cancer: a late event? Oncogene (1991) 1.13
Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer (1998) 1.13
The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun (1986) 1.12
Immunosuppressive effect of rifampicin. Transplantation (1972) 1.11
Differential interaction of nuclear receptors with the putative human transcriptional coactivator hTIF1. J Biol Chem (1997) 1.11
Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res (1990) 1.10
Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem (1993) 1.10
Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci U S A (1996) 1.10
Several thaumatin-like proteins bind to beta-1,3-glucans. Plant Physiol (1998) 1.10
Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors. Ann Oncol (1997) 1.10
SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol (1995) 1.09
Effect of estradiol on the ultrastructure of the MCF7 human breast cancer cells in culture. Cancer Res (1982) 1.08
Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers? Invasion Metastasis (1995) 1.08
Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol (1986) 1.07
Androgens induce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP human prostate cancer cells. Mol Cell Endocrinol (2001) 1.07
Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. J Cell Sci (1994) 1.07
Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin. Int J Cancer (1998) 1.06
Detection of beta-1,3-glucanase activity after native polyacrylamide gel electrophoresis: application to tobacco pathogenesis-related proteins. Electrophoresis (1989) 1.05
Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol Endocrinol (1989) 1.05
Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol (2000) 1.05
Mouse mammary tumour virus related sequences are present in human DNA. Nucleic Acids Res (1983) 1.04
Late-onset adrenal hyperplasia in hirsutism. N Engl J Med (1985) 1.03
Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells (1996) 1.02
High-affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogen metabolite. Mol Cell Endocrinol (1980) 1.02
A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer (1993) 1.02
Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients. Cancer (1988) 1.02
Osseous metastases in the hand. A general review of three cases. Ann Chir Main (1982) 1.01
Evaluation of endometrial inflammation by quantification of macrophages, T lymphocytes, and interleukin-1 and -6 in human endometrium. J Assist Reprod Genet (1998) 1.01
Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer (2000) 1.01
Steroid hormone receptors. Vitam Horm (1975) 1.00
Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors. Cell Growth Differ (1995) 0.99
Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J Biol Chem (1994) 0.99
The prognostic value of cathepsin D in breast cancer. A long road to the clinic. Eur J Cancer (1996) 0.99
Accumulation of beta-Fructosidase in the Cell Walls of Tomato Roots following Infection by a Fungal Wilt Pathogen. Plant Physiol (1991) 0.99
In vitro culture reduces immunogenicity of pancreatic endocrine islets. Nature (1978) 0.99
Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer (1997) 0.99
Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology (2004) 0.98
Formation of estrogen nuclear receptor in uterus: effect of androgens, estrone and nafoxidine. Biochem Biophys Res Commun (1972) 0.98